Results 251 to 260 of about 410,880 (314)

Estradiol levels in women with hormone receptor-positive advanced breast cancer on fulvestrant therapy. [PDF]

Oncologist
Dai S, Wen Y, Wu X, Wang X, Yuan Z, Xu F, Xie X, Xia W, Wang S, Shi Y, Liu P, Zheng Q, Tang J, An X, Huang J, Chen M, Zhong Y, Bi X, Yang Y, Xue C.   +19 more
europepmc   +1 more source

breast cancer, advanced

Annals of Oncology, 2006
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Advances in the Treatment of Breast Cancer

Clinical Pharmacology & Therapeutics, 2007
Breast cancer is the most commonly diagnosed cancer in American women and is the second leading cause of cancer-related deaths in this population. This review highlights how the use of a multidisciplinary approach to the management of diseases of the breast and the introduction of novel systemic therapies have improved the quality of life and survival ...
S, Moulder, G N, Hortobagyi
openaire   +2 more sources

Zoladex in Advanced Breast Cancer

Hormone Research, 2008
In the treatment of 53 premenopausal patients with advanced breast cancer, the LHRH analogue, Zoladex (goserelin), produced a response rate similar to that of surgical oophorectomy. Endocrinologically, Zoladex caused castrate levels of serum oestradiol and progesterone except in a small number of patients, where intermittent, suppressed peaks of ...
J F, Robertson, R I, Nicholson, K J, Walker, R W, Blamey   +3 more
openaire   +2 more sources

LOCALLY ADVANCED BREAST CANCER

Hematology/Oncology Clinics of North America, 1999
The multidisciplinary management of patients with locally advanced breast cancer (LABC) has evolved over the last three decades. The introduction of chemotherapy (CT) and endocrine therapy in conjunction with surgery and radiation therapy (XRT) have changed the natural history of this disease.
F J, Esteva, G N, Hortobagyi
openaire   +2 more sources

Locally advanced breast cancer

Current Opinion in Obstetrics and Gynecology, 2006
The management of locally advanced breast cancer requires a combined-modality treatment approach involving surgery, radiotherapy and systemic therapy. In this paper, we review clinical and experimental studies in order to evaluate how basic and clinical research in locally advanced breast cancer has progressed in the past year.
Sandro, Barni, Mario, Mandalà
openaire   +2 more sources

Locally advanced breast cancer

Oncology Reports, 1996
In vitro studies suggest p53 and bcl-2 may be important in the apoptotic response to irradiation, and that rapidly proliferating cells are more sensitive to radiotherapy. The clinical relevance of biological factors in predicting radiotherapy response was investigated in 62 patients with locally advanced breast cancer.
P, Willsher, N, Kapucuoglu, I, Ellis, S, Chan, R, Blamey, J, Robertson   +5 more
openaire   +2 more sources